Natural dipeptidyl peptidase-IV inhibitor mangiferin mitigates diabetes- and metabolic syndrome-induced changes in experimental rats
Rajesh Kumar Suman,1 Ipseeta Ray Mohanty,1 Ujwala Maheshwari,2 Manjusha K Borde,1 YA Deshmukh1 1Department of Pharmacology, 2Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai, India Background: Mangiferin (MNG) is known to possess antidiabetic and antioxidant activity. However, ther...
Enregistré dans:
Auteurs principaux: | Suman RK, Mohanty IR, Maheshwari U, Borde MK, Deshmukh YA |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f155ada8cef845c083ab819c9ee54af3 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Mangiferin Mitigates Lipopolysaccharide-Induced Lung Injury by Inhibiting NLRP3 Inflammasome Activation
par: Li N, et autres
Publié: (2021) -
The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
par: Aleksander Sergeevich Ametov, et autres
Publié: (2015) -
Mangiferin: Analgesic properties in neuropathic pain, molecular docking and meta-analysis
par: Bo-tao Chang, et autres
Publié: (2022) -
Mangiferin Inhibits Apoptosis and Autophagy Induced by Staphylococcus aureus in RAW264.7 Cells
par: Xu J, et autres
Publié: (2020) -
Peripheral Neuropathy Presents Similar Symptoms and Pathological Changes in Both High-Fat Diet and Pharmacologically Induced Pre- and Diabetic Mouse Models
par: Julia Jaroslawska, et autres
Publié: (2021)